Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

A viral load and anti-retroviral technology, applied in antiviral agents, gene therapy, drug combinations, etc.

Active Publication Date: 2021-08-13
IMMUNOVATIVE THERAPIES
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the lack of suitable donors and the toxicity of the allogeneic transplantation procedure made it impossible to convert the data from this Berlin patient to benefit the majority of HIV-infected patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] During the initial protocol phase, patients were maintained on HAART. After a peak in viral load was detected, indicating successful activation of latent virus, viral load subsequently decreased to baseline, indicating that immunocontrolled patients could be eligible for the HAART interruption phase.

[0106] To minimize the risk of treatment interruption, patients are closely monitored and treatment should be resumed if viral replication is detected.

[0107] In patients on HAART, the regimen is to administer AlloStim intradermally TM and escalating intravenous doses of AlloStim TM alternate between. The purpose of intradermal administration is to increase the titer of circulating CD4+ Th1 memory cells against HIV infectivity. The purpose of the intravenous infusion is to deliver an inflammatory cytokine storm and activated CD4 memory cells and macrophages (via CD40-CD40L). Activation should stimulate latent viral replication within these depots. In addition, intr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
clearance rateaaaaaaaaaa
Login to View More

Abstract

Methods of treating patients with human immunodeficiency virus are disclosed. The method includes providing an intradermal dose and an intravenous dose of an aTh1 composition that increases HIV-resistant CD4+ cells in a patient. The instructions include a viral load reduction method and a viral clearance method. This regimen results in a spike in viral load followed by a return to sub-baseline levels of virus and may result in a reduction and / or elimination of potential viral reservoirs. Also included are kits configured to provide intradermal and intravenous doses according to the protocol.

Description

technical field [0001] The present invention relates to treatment with antiretroviral therapy, and more particularly to immunotherapy for HIV / AIDS. Background technique [0002] AIDS was first reported in the United States in 1981, and has since become a major epidemic worldwide. AIDS is caused by the human immunodeficiency virus, or HIV. Today, more than 30 million people living around the world are infected with the virus (Cohen, Hellmann et al. 2008). HIV works by killing or destroying cells of the body's immune system, specifically by eliminating cells expressing CD4 molecules such as CD4+ helper T lymphocytes (resulting in a reversed CD4 / CD8 T-cell ratio) and cells of the monocyte / macrophage lineage (Fauci 1996 )) immune cells and gradually destroy the body's ability to fight infection and other diseases. [0003] CD4 T cells mature into two polarized functional types, termed aTh1 and Th2 (Mosmann and Coffman 1989; Mosmann and Sad 1996). Th1 CD4+ cells are responsib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K48/00A61K35/17A61K39/21A61K31/18
CPCA61K35/17A61K45/06A61P31/18A61P37/04A61K39/21A61K39/0005A61K9/0019
Inventor 迈克尔·哈尔-诺伊
Owner IMMUNOVATIVE THERAPIES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com